HONG KONG – Seongnam-Si, South Korea-based ABL Bio Inc. hopes to file IND applications for two solid tumor-focused bispecific antibodies (BsAb), CEO Sang-hoon Lee, told the 2020 Bioplus Interphex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback